Special Issue

Epigenetics of Prostate Cancer

Message from the Guest Editor

I am pleased to invite you to contribute to this Special Issue, the aim of which is to present original research articles, perspectives and reviews that expand our understanding of the epigenetic basis of prostate cancers, how these contribute to metastasis, their resistance to standard of care therapies and the critical roles they play in immune suppression. In this Special Issue, original research articles, perspectives and reviews are welcome. Research areas may include (but are not limited to) the following:

- Epigenetic modifications of histones and transcription factors driving prostate cancer.
- Mechanism-based epigenetic therapies targeting castration resistance.
- Non-coding RNAs' mechanism-based understanding of function in prostate cancer progression.
- Chromatin factors and transcription factors crosstalk in drug resistance.
- Epigenetics of immune suppression of prostate cancer.
- Synergy between DNA damage response and epigenetic alterations in recurrence and metastasis.
- Metabolism-induced epigenetic changes and drug resistance.

I look forward to receiving your contributions.

Guest Editor

Dr. Kiran Mahajan

- 1. Department of Surgery, Cancer Research Building, Washington University in St. Louis, St. Louis, MO 63110, USA
- 2. Department of Urology, Cancer Research Building, Washington University in St. Louis, St. Louis, MO 63110, USA
- 3. Siteman Cancer Center, Cancer Research Building, Washington University in St. Louis, St. Louis, MO 63110, USA

Deadline for manuscript submissions

closed (31 August 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/181720

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

